Holen Sie sich die Stockscreener-App
1.31
2.34%
0.03
Schlusskurs vom Vortag:
$1.28
Offen:
$1.3
24-Stunden-Volumen:
289.84K
Relative Volume:
0.37
Marktkapitalisierung:
$81.11M
Einnahmen:
$248.00K
Nettoeinkommen (Verlust:
$-149.34M
KGV:
-0.538
EPS:
-2.4348
Netto-Cashflow:
$-128.71M
1W Leistung:
+2.34%
1M Leistung:
+2.34%
6M Leistung:
-9.03%
1J Leistung:
-12.08%
1-Tages-Spanne:
$1.30
$1.335
1-Wochen-Bereich:
$1.255
$1.335
52-Wochen-Spanne:
$1.09
$1.95
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Firmenname
Pliant Therapeutics Inc
Sektor
Branche
Telefon
650-481-6770
Adresse
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.31 | 81.11M | 248.00K | -149.34M | -128.71M | -2.4348 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-03-04 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2025-03-04 | Herabstufung | Needham | Buy → Hold |
| 2025-03-03 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-03-03 | Herabstufung | Stifel | Buy → Hold |
| 2025-02-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2025-02-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-02-10 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-02-10 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2025-02-10 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-02-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-09-09 | Fortgesetzt | Leerink Partners | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-18 | Eingeleitet | Canaccord Genuity | Buy |
| 2023-04-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Buy |
| 2022-12-07 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-07-20 | Eingeleitet | SVB Leerink | Outperform |
| 2022-05-25 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-10 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-24 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-11-03 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-04-20 | Eingeleitet | BTIG Research | Buy |
| 2021-04-05 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Citigroup | Buy |
| 2020-06-29 | Eingeleitet | Cowen | Outperform |
| 2020-06-29 | Eingeleitet | Needham | Buy |
| 2020-06-29 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Pliant Therapeutics Inc Aktie (PLRX) Neueste Nachrichten
Sentiment Recap: Is Pliant Therapeutics Inc still a buy after recent gains2026 Key Lessons & Weekly Watchlist for Consistent Profits - baoquankhu1.vn
If You Invested $1,000 in Pliant Therapeutics, Inc. (PLRX) - Stock Titan
Analyst Calls: Is Pliant Therapeutics Inc benefiting from interest rate changesWeekly Profit Recap & AI Enhanced Trading Signals - baoquankhu1.vn
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR By Investing.com - Investing.com South Africa
Pliant Therapeutics to present PLN-101095 cancer trial data at AACR - Investing.com Australia
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting - Investing News Network
AACR 2026 to feature Pliant Therapeutics Phase 1 PLN-101095 results at major symposium - Traders Union
Pliant Therapeutics Announces Upcoming Presentation Of Phase 1 Clinical Trial Of PLN-101095 In Patients With Solid Tumors At The 2026 Aacr Annual Meeting - TradingView
Clinical Progress and Disclosure Timeline: Biopharmaceutical company Pliant Therapeutics (NASDAQ: PLRX) announced that Phase I clinical trial data for its solid tumor candidate drug Pln-101095 will be officially released at the 2026 American Association f - Bitget
Portfolio Shifts: Is Pliant Therapeutics Inc benefiting from interest rate changes2026 Earnings Impact & Consistent Profit Alerts - baoquankhu1.vn
Prosight Management Cuts Stake in Pliant Therapeutics - National Today
Prosight Management LP Has $30,000 Position in Pliant Therapeutics, Inc. $PLRX - MarketBeat
How Shareholder Activism Could Disrupt Pliant Therapeutics’ Strategy, Costs, and Stock Performance - The Globe and Mail
Oppenheimer Remains a Hold on Pliant Therapeutics (PLRX) - The Globe and Mail
Pliant Therapeutics (PLRX): Canaccord Genuity Adjusts Price Targ - GuruFocus
Canaccord Genuity Group Issues Pessimistic Forecast for Pliant Therapeutics (NASDAQ:PLRX) Stock Price - MarketBeat
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD) - The Globe and Mail
Analysts Have Conflicting Sentiments on These Healthcare Companies: Pliant Therapeutics (PLRX) and Cytokinetics (CYTK) - The Globe and Mail
Pliant Therapeutics (PLRX) Analyst Rating Update: Piper Sandler Lowers Price Target | PLRX Stock News - GuruFocus
Piper Sandler cuts Pliant Therapeutics stock price target to $3 By Investing.com - Investing.com Canada
Pliant Therapeutics Reports Q4 2025 Financial Results and Corporate Update – 8-K Filing Summary - Minichart
Pliant Therapeutics 2025 Annual Report: Business Overview, Risks, Regulatory Environment, and Competitive Landscape - Minichart
Pliant Therapeutics (PLRX) Advances Oncology Drug Development - GuruFocus
Pliant Therapeutics (NASDAQ:PLRX) Posts Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
PLRX: Net loss improved to $149.3M as focus shifted to PLN-101095; $192.4M cash on hand - TradingView
Pliant Therapeutics 10‑K — No Revenue; Net Loss $2.43 EPS on $149.3M Net Loss - TradingView
PLRX: PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses - TradingView
Oncology data and cost cuts reshape Pliant Therapeutics (NASDAQ: PLRX) - Stock Titan
BRIEF-Pliant Therapeutics Q4 Net Income USD -23.577 Million - TradingView
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results - ChartMill
Market Rankings: Is Pliant Therapeutics Inc stock good for income investorsQuarterly Profit Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Lyell Immunopharma, Inc. Announces Chief Financial Officer Changes - marketscreener.com
Pliant Therapeutics Extends Stockholder Rights Agreement Expiration - The Globe and Mail
PLRX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Pliant Therapeutics (PLRX) extends stockholder rights plan expiration to 2027 - Stock Titan
Pliant Therapeutics Pivots to Oncology, Highlights Early PLN-101095 Responses at Oppenheimer Conference - Yahoo Finance
PLRX Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Pliant Therapeutics Inc expected to post a loss of 40 cents a shareEarnings Preview - TradingView
Momentum Shift: Is M I Homes Inc currently under institutional pressure2025 Technical Overview & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn
PLRX SEC FilingsPliant Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PLRX: Lead oncology program shows strong early efficacy and safety, with phase Ib starting in Q2 - TradingView
Analysts Are Neutral on These Healthcare Stocks: Pliant Therapeutics (PLRX), Summit Therapeutics (SMMT) - The Globe and Mail
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of "Reduce" from Analysts - MarketBeat
Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration - Seeking Alpha
Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference - The Manila Times
Pliant Therapeutics (PLRX) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Investment Recap: What is the Moat Score of Pliant Therapeutics IncJuly 2025 Patterns & AI Optimized Trade Strategies - baoquankhu1.vn
PLRX Should I Buy - Intellectia AI
Should I hold or sell Pliant Therapeutics Inc. stock in 20252025 Winners & Losers & Short-Term Swing Trade Alerts - mfd.ru
PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - GuruFocus
Finanzdaten der Pliant Therapeutics Inc-Aktie (PLRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):